Knight Therapeutics Strengthens Portfolio in Brazil

MT newswire2026/10/06 12:33

08:33 AM EDT, 10/06/2026 (MT Newswires) -- Knight Therapeutics (GUD.TO) expanded its portfolio in Brazil after securing regulatory approval for NIKTIMVO and launching TAVALISSE, the pharmaceutical company said Tuesday. NIKTIMVO is used to treat chronic graft-versus-host disease, while TAVALISSE is used to treat chronic immune thrombocytopenia, the company said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.